These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33059604)

  • 1. Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
    Stockley J; Akhand R; Kennedy A; Nyberg C; Crosbie EJ; Edmondson RJ
    BMC Cancer; 2020 Oct; 20(1):1000. PubMed ID: 33059604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosomal Maintenance Component Complex 5 (MCM5) as a Marker of Barrett's Esophagus-Related Neoplasia: A Feasibility Study.
    Everson M; Magee C; Alzoubaidi D; Brogden S; Graham D; Lovat LB; Novelli M; Haidry R
    Dig Dis Sci; 2019 Oct; 64(10):2815-2822. PubMed ID: 30982210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study.
    Záveský L; Jandáková E; Turyna R; Langmeierová L; Weinberger V; Záveská Drábková L; Hůlková M; Hořínek A; Dušková D; Feyereisl J; Minář L; Kohoutová M
    Pathol Oncol Res; 2015 Sep; 21(4):1027-35. PubMed ID: 25827090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments.
    Stoeber K; Swinn R; Prevost AT; de Clive-Lowe P; Halsall I; Dilworth SM; Marr J; Turner WH; Bullock N; Doble A; Hales CN; Williams GH
    J Natl Cancer Inst; 2002 Jul; 94(14):1071-9. PubMed ID: 12122098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular urinary microRNAs as non-invasive biomarkers of endometrial and ovarian cancer.
    Hanžek A; Siatka C; Duc AE
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7981-7993. PubMed ID: 36914786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine.
    Brisuda A; Háček J; Čechová M; Škapa P; Babjuk M
    Cytopathology; 2019 Sep; 30(5):510-518. PubMed ID: 30943322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of endometrial cancer using tampon-based collection and methylated DNA markers.
    Bakkum-Gamez JN; Sherman ME; Slettedahl SW; Mahoney DW; Lemens MA; Laughlin-Tommaso SK; Hopkins MR; VanOosten A; Shridhar V; Staub JK; Cao X; Foote PH; Clarke MA; Burger KN; Berger CK; O'Connell MC; Doering KA; Podratz KC; DeStephano CC; Schoolmeester JK; Kerr SE; Wentzensen N; Taylor WR; Kisiel JB
    Gynecol Oncol; 2023 Jul; 174():11-20. PubMed ID: 37141817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of mid-infrared spectroscopy as a non-invasive diagnostic test in urine for endometrial or ovarian cancer.
    Paraskevaidi M; Morais CLM; Lima KMG; Ashton KM; Stringfellow HF; Martin-Hirsch PL; Martin FL
    Analyst; 2018 Jun; 143(13):3156-3163. PubMed ID: 29878018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review.
    Kwinten KJJ; Lemain VA; de Hullu JA; Leenders WPJ; Steenbeek MP; van Altena AM; Pijnenborg JMA
    Cancer Med; 2024 Jul; 13(14):e70000. PubMed ID: 39031958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HE4 as a biomarker for ovarian and endometrial cancer management.
    Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
    Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection.
    Sangtani A; Wang C; Weaver A; Hoppman NL; Kerr SE; Abyzov A; Shridhar V; Staub J; Kocher JA; Voss JS; Podratz KC; Wentzensen N; Kisiel JB; Sherman ME; Bakkum-Gamez JN
    Gynecol Oncol; 2020 Feb; 156(2):387-392. PubMed ID: 31787246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
    Bakkum-Gamez JN; Wentzensen N; Maurer MJ; Hawthorne KM; Voss JS; Kroneman TN; Famuyide AO; Clayton AC; Halling KC; Kerr SE; Cliby WA; Dowdy SC; Kipp BR; Mariani A; Oberg AL; Podratz KC; Shridhar V; Sherman ME
    Gynecol Oncol; 2015 Apr; 137(1):14-22. PubMed ID: 25677060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive detection of endometrial cancer by DNA methylation analysis in urine.
    van den Helder R; Wever BMM; van Trommel NE; van Splunter AP; Mom CH; Kasius JC; Bleeker MCG; Steenbergen RDM
    Clin Epigenetics; 2020 Nov; 12(1):165. PubMed ID: 33143739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.
    Chang CC; Wang HC; Liao YP; Chen YC; Weng YC; Yu MH; Lai HC
    J Gynecol Oncol; 2018 Jan; 29(1):e17. PubMed ID: 29185275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supernatant versus exosomal urinary microRNAs. Two fractions with different outcomes in gynaecological cancers.
    Zavesky L; Jandakova E; Turyna R; Langmeierova L; Weinberger V; Minar L
    Neoplasma; 2016; 63(1):121-32. PubMed ID: 26639242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fourier-transform infrared spectroscopy coupled with a classification machine for the analysis of blood plasma or serum: a novel diagnostic approach for ovarian cancer.
    Gajjar K; Trevisan J; Owens G; Keating PJ; Wood NJ; Stringfellow HF; Martin-Hirsch PL; Martin FL
    Analyst; 2013 Jul; 138(14):3917-26. PubMed ID: 23325355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
    Wang Y; Li L; Douville C; Cohen JD; Yen TT; Kinde I; Sundfelt K; Kjær SK; Hruban RH; Shih IM; Wang TL; Kurman RJ; Springer S; Ptak J; Popoli M; Schaefer J; Silliman N; Dobbyn L; Tanner EJ; Angarita A; Lycke M; Jochumsen K; Afsari B; Danilova L; Levine DA; Jardon K; Zeng X; Arseneau J; Fu L; Diaz LA; Karchin R; Tomasetti C; Kinzler KW; Vogelstein B; Fader AN; Gilbert L; Papadopoulos N
    Sci Transl Med; 2018 Mar; 10(433):. PubMed ID: 29563323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial.
    Tarney CM; Wang G; Bateman NW; Conrads KA; Zhou M; Hood BL; Loffredo J; Tian C; Darcy KM; Hamilton CA; Casablanca Y; Lokshin A; Conrads TP; Maxwell GL
    Am J Obstet Gynecol; 2019 Nov; 221(5):472.e1-472.e10. PubMed ID: 31279844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of SELDI-TOF in N-glycopeptides profiling of the urine from patients with endometrial, ovarian and cervical cancer.
    Mu AK; Lim BK; Aminudin N; Hashim OH; Shuib AS
    Arch Physiol Biochem; 2016 Jul; 122(3):111-6. PubMed ID: 26849673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.